β-Adrenergic receptor antagonism in mice: a model for pediatric heart disease

Children with heart failure are treated with similar medical therapy as adults with heart failure. In contrast to adults with heart failure, these treatment regiments are not associated with improved outcomes in children. Recent studies have demonstrated age-related pathophysiological differences in the molecular mechanisms of heart failure between children and adults. There are no animal models of pediatric cardiomyopathy to allow mechanistic studies. The purpose of the current experiments was to develop a mouse model of pediatric heart disease and test whether the influence of beta-adrenergic receptor (beta-AR) antagonism could be modeled in this system. We hypothesized that isoproterenol treatment of young mice would provide a model system of cardiac pathology, and that nonselective beta-AR blockade would provide benefit in adult, but not young, mice, similar to clinical trial data. We found that isoproterenol treatment (through osmotic minipump implantation) of young and adult mice produced similar degrees of cardiac hypertrophy and recapitulated several age-related molecular abnormalities in human heart failure, including phospholamban phosphorylation and beta-AR expression. We also found that nonselective beta-AR blockade effectively prevented pathological cardiac growth and collagen expression in the adult but not young mice, and that selective beta(1)-AR blockade was effective in both young and adult isoproterenol-treated mice. In conclusion, we have developed the first model system for beta-AR-mediated pediatric heart disease. Furthermore, we have generated novel data suggesting beneficial effects of selective beta(1)-AR blockade in the pediatric heart.